Handling of Control Samples in Pharma

Handling of Control Samples in Pharma: Complete GMP Guide 2026

In pharmaceutical manufacturing, Control Samples and Retention Samples act as legal proof of what was released to market. If there’s a complaint, recall, or regulatory audit after 2 years, these are the samples that save you.

This blog covers WHO, USFDA, EU GMP Annex 19, and Schedule M requirements for collection, storage, retention, and destruction of control samples.

Quick Definition: A Control Sample is a representative quantity of a finished product batch retained for testing and investigation purposes, stored in the final container closure system.

1. Regulatory Requirements for Control Samples

Guideline Requirement
WHO TRS 986 Annex 2 2x full QC quantity. Store in final pack. Retain 1 year after expiry
USFDA 21 CFR 211.170 Reserve sample = 2x testing. Retain 1 year after expiry
EU GMP Annex 19 Reference + Retention sample. Store under label conditions
Schedule M, India 1 year after expiry OR 3 years after distribution, whichever is later

2. Types of Samples in Pharma

A. Reference Sample

Used for analytical testing. Quantity: Minimum 2 times the quantity required to conduct all QC tests as per pharmacopoeia.

B. Retention Sample

Used for visual/physical examination. Usually 1 unit in final market pack. Helps during complaint investigation.

C. Stability Sample

Kept in stability chambers per ICH Q1A. Separate from control sample room.

3. SOP for Handling of Control Samples

Step 1: Collection & Labeling

  • Collect from the batch that is released for distribution
  • Must be in final market container and label
  • Label details: Product Name, Batch No, Mfg & Exp Date, Quantity, Storage Condition, “CONTROL SAMPLE – NOT FOR SALE”
  • Transfer from Production → QC → Control Sample Room via documented challan

Step 2: Storage Conditions

  • Dedicated Control Sample Room with restricted access
  • Temperature & Humidity mapping: 25°C ±2°C / 60% RH ±5% or 2-8°C as per label
  • 24×7 continuous monitoring with alarm and data backup
  • Segregation: By product, dosage form, and year of manufacturing

Step 3: Documentation & Inventory

  • Control Sample Register / LIMS module
  • Quarterly physical verification by QA
  • Sample issue record if used for investigation

Step 4: Retention Period

Global: 1 year after expiry date of batch
India: 1 year after expiry OR 3 years after batch distribution, whichever is later

Example: Batch Expiry: Dec 2026 → Retain till Dec 2027

Step 5: Destruction

  • Take QA Head approval after retention period
  • Destruction by incineration/shredding as per waste management SOP
  • Maintain Destruction Record with 2 witnesses
Audit Alert: Most common USFDA 483 observations:
1. No temperature monitoring in sample room
2. Samples not in final container
3. Insufficient quantity for retesting

4. Best Practices

  • Barcoding & LIMS: Each sample tagged for traceability
  • Dual Access Control: 2-person rule to enter sample room
  • Mock Recall: Retrieve 1 control sample yearly to test process
  • PE Risk: Ensure control samples are never used for commercial supply

5. Common Mistakes to Avoid

  1. Storing bulk samples instead of finished pack
  2. Keeping less than 2x testing quantity
  3. No access log for sample room
  4. Destroying before approved retention period
  5. Missing temperature excursion investigation

Conclusion

Control sample management is a direct reflection of a company’s GMP maturity. A well-managed sample room means you can respond to any complaint or audit in < 30 minutes with full traceability.

As per USFDA and other global regulatory authorities: “If you can’t produce the sample, it’s as good as you never made the batch.”

Regulatory Disclaimer:
The information provided in this article is for educational and informational purposes only.
It is based on WHO TRS, USFDA 21 CFR, EU GMP Annex 19, and Schedule M as of July 2026.
Readers should always refer to their company SOPs, latest regulatory guidelines, and consult
with Qualified Persons/QA Heads before implementing any practice. PharmaShare does not assume
responsibility for any errors or actions taken based on this content.

Mahummed Asif - Pharma QA Expert

About the Author

Mahummed Asif is a experienced pharmaceutical QA professional and publisher of Pharmashare. He has sound knowledge in GMP, Product Life Cycle Management, Regulatory filing, QMS, Product Complaint Management, Change control, risk management, and global audit preparation.

Leave a Comment